Similarly, PCSK9, CETP andAPOC3 inhibition proxies reduced the risk of AAA (OR: 0.595, 95% CI:0.485–0.730, p = 6.75 × 10-7, OR: 0.127, 95% CI:0.066–0.243, p = 4.42 × 10-10, and OR: 0.387, 95% CI:0.182–0.824, p = 0.014, respectively) while showing a neutral impact onTAA and AD. Here, PCSK9 is linked to triple-A syndrome.